Holen Sie sich die Stockscreener-App
37.30
0.64%
-0.24
Handel nachbörslich:
37.30
Schlusskurs vom Vortag:
$37.54
Offen:
$37.52
24-Stunden-Volumen:
3.70M
Relative Volume:
0.97
Marktkapitalisierung:
$16.12B
Einnahmen:
$2.31B
Nettoeinkommen (Verlust:
$1.66B
KGV:
16.24
EPS:
2.297
Netto-Cashflow:
$827.02M
1W Leistung:
+0.11%
1M Leistung:
+3.41%
6M Leistung:
+13.41%
1J Leistung:
+37.64%
1-Tages-Spanne:
$37.13
$37.72
1-Wochen-Bereich:
$35.91
$37.72
52-Wochen-Spanne:
$24.05
$38.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Vergleichen Sie RPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
37.30 | 16.23B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma PLC $RPRX is Torray Investment Partners LLC's 3rd Largest Position - MarketBeat
Tredje AP fonden Increases Stake in Royalty Pharma PLC $RPRX - MarketBeat
Will Royalty Pharma plc (RPD) stock maintain strong growthPortfolio Return Report & Community Trade Idea Sharing - newser.com
Will Royalty Pharma plc (RPD) stock hit Wall Street targetsJobs Report & Weekly Breakout Opportunity Watchlist - newser.com
Is Royalty Pharma plc stock a top momentum playWeekly Stock Report & Weekly Setup with High ROI Potential - newser.com
Why Royalty Pharma plc (RPD) stock could outperform next year2025 Technical Overview & Safe Entry Trade Signal Reports - newser.com
What MACD signals say about Royalty Pharma plcMarket Movement Recap & Low Risk Investment Opportunities - newser.com
8,849 Shares in Royalty Pharma PLC $RPRX Acquired by MMA Asset Management LLC - MarketBeat
Royalty Pharma PLC $RPRX is Regal Partners Ltd's 9th Largest Position - MarketBeat
Top chart patterns to watch in Royalty Pharma plcStock Surge & Risk Managed Investment Strategies - newser.com
Is Royalty Pharma plc stock a safe investment in uncertain marketsWeekly Loss Report & Reliable Intraday Trade Plans - newser.com
Applying chart zones and confluence areas to Royalty Pharma plcInsider Buying & Short-Term High Return Ideas - newser.com
Royalty Pharma plc : Close to an important technical resistance levels - MarketScreener
Why analysts remain bullish on Royalty Pharma plc stockEarnings Trend Report & AI Enhanced Trading Alerts - newser.com
Historical volatility pattern of Royalty Pharma plc visualizedLong Setup & Risk Controlled Swing Alerts - newser.com
What the charts say about Royalty Pharma plc todayQuarterly Trade Review & Stock Market Timing Techniques - newser.com
Can Royalty Pharma plc stock beat analyst upgradesProfit Target & Fast Gain Swing Trade Alerts - newser.com
Detecting support and resistance levels for Royalty Pharma plcMarket Trend Report & Fast Entry Momentum Alerts - newser.com
How Royalty Pharma plc (RPD) stock performs in easing cycles2025 Market Trends & Growth Focused Stock Pick Reports - newser.com
28,646 Shares in Royalty Pharma PLC $RPRX Bought by Nisa Investment Advisors LLC - MarketBeat
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks - MSN
Using Python tools to backtest Royalty Pharma plc strategiesMarket Trend Report & Stock Portfolio Risk Control - newser.com
Quantitative breakdown of Royalty Pharma plc recent moveWall Street Watch & Risk Managed Investment Signals - newser.com
Royalty Pharma (NASDAQ:RPRX) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
What drives Royalty Pharma plc stock priceMarket Sentiment Extremes & Low Risk Trading Ideas - earlytimes.in
Royalty Pharma PLC $RPRX Shares Purchased by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
Is Royalty Pharma plc reversing from oversold territoryJuly 2025 Sentiment & Stepwise Trade Execution Plans - newser.com
Impact Partnership Wealth LLC Purchases 12,329 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Assessing Royalty Pharma (RPRX) Valuation After Recent Momentum in 2024 - Sahm
What’s the recovery path for long term holders of Royalty Pharma plcTrade Exit Summary & Free Safe Entry Trade Signal Reports - newser.com
What indicators show strength in Royalty Pharma plcJuly 2025 Analyst Calls & AI Powered Buy and Sell Recommendations - newser.com
Why retail investors pile into Royalty Pharma plc stockQuarterly Trade Report & AI Forecasted Entry and Exit Points - newser.com
Why Royalty Pharma plc (RPD) stock could rally stronglyQuarterly Market Review & Community Consensus Trade Signals - newser.com
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.35%
1.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):